ArticleNeurology2026
Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMulti-arm multistage (MAMS) clinical trials use interim outcome stage analyses to test multiple candidate treatments, determining which should proceed to the next trial stage. The reduced time, cost, and participant numbers, compared with current separated phases 2 and 3 clinical trials, could expedite the development of treatments in neurodegenerative diseases, such as progressive multiple sclerosis (PMS). MAMS trial interim outcomes must reflect the final stage outcome and be able to detect treatment effects with high power at interim stages. Patient-reported outcomes (PROMs) are cost-effective and highly accessible, making them promising MAMS trial interim outcome measures. We determined whether the MS Quality of Life 54 Physical Health Composite, MS Impact Scale 29 version 2 physical health subscore (MSIS-29v2 PH), MS Walking Scale 12 version 2 (MSWS-12v2), or their composite could act as interim outcome measures in MAMS PMS trials.
methodsUsing a pooled analysis of 11,052 longitudinal visits from 3 PMS trials, we assessed the relationship of PROM change at early time points with 6-month confirmed disability progression (CDP) in the Expanded Disability Status Scale (EDSS) up to 36 months through Cox proportional hazards. To minimize PROM ceiling effects, we generated an MSIS-29v2 PH and MSWS-12v2 composite, prioritizing greatest change. We calculated the required sample size when these PROMs were used as interim measures.
resultsWe analyzed 1,927 of the 2,046 available participants (mean age 54 [SD 7.2] years and 66% female). EDSS 6-month CDP risk was significantly associated with each 1-standard deviation 12-month score increase for the MSIS-29v2 PH (hazard ratio [HR] 1.20 [1.08-1.33]), MSWS-12v2 (HR 1.26 [1.13-1.40]), and composite (HR 1.29 [1.16-1.44]; all DISCUSSION: Changes in the MSIS-29v2 PH, MSWS-12v2, and composite scores associated with ≥6-month EDSS CDP up to 36 months. The composite has sufficient statistical power to detect treatment effects at 12 months. These PROMs are well placed to play a role in interim analysis in MAMS trials in PMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.